AQUABOUNTY TECHNOLOGIES (AQB)
US03842K3095 - Common Stock
AQB gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. Both the profitability and financial health of AQB have multiple concerns. AQB is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year AQB has reported negative net income.
AQB had a negative operating cash flow in the past year.
In the past 5 years AQB always reported negative net income.
In the past 5 years AQB always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of AQB (-14.70%) is better than 86.99% of its industry peers.
With an excellent Return On Equity value of -16.70%, AQB belongs to the best of the industry, outperforming 89.21% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.7% | ||
| ROE | -16.7% | ||
| ROIC | N/A |
ROA(3y)-11.61%
ROA(5y)-18.33%
ROE(3y)-12.9%
ROE(5y)-21.71%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AQB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
AQB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AQB has less shares outstanding
AQB has less shares outstanding than it did 5 years ago.
AQB has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -1.93, we must say that AQB is in the distress zone and has some risk of bankruptcy.
AQB has a Altman-Z score (-1.93) which is in line with its industry peers.
AQB has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
AQB has a worse Debt to Equity ratio (0.05) than 60.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.93 |
ROIC/WACCN/A
WACC5.77%
2.3 Liquidity
A Current Ratio of 0.80 indicates that AQB may have some problems paying its short term obligations.
AQB's Current ratio of 0.80 is on the low side compared to the rest of the industry. AQB is outperformed by 91.78% of its industry peers.
AQB has a Quick Ratio of 0.80. This is a bad value and indicates that AQB is not financially healthy enough and could expect problems in meeting its short term obligations.
AQB's Quick ratio of 0.68 is on the low side compared to the rest of the industry. AQB is outperformed by 93.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.8 | ||
| Quick Ratio | 0.68 |
3. Growth
3.1 Past
The earnings per share for AQB have decreased strongly by -19.19% in the last year.
The Revenue for AQB has decreased by -20.88% in the past year. This is quite bad
AQB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 98.62% yearly.
EPS 1Y (TTM)-19.19%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-36.87%
Revenue 1Y (TTM)-20.88%
Revenue growth 3Y166.94%
Revenue growth 5Y98.62%
Revenue growth Q2Q22.94%
3.2 Future
Based on estimates for the next years, AQB will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.23% on average per year.
Based on estimates for the next years, AQB will show a very strong growth in Revenue. The Revenue will grow by 95.02% on average per year.
EPS Next Y38.09%
EPS Next 2Y25.52%
EPS Next 3Y0.17%
EPS Next 5Y14.23%
Revenue Next Year-12.67%
Revenue Next 2Y-20.84%
Revenue Next 3Y-42.53%
Revenue Next 5Y95.02%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
AQB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AQB. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.52%
EPS Next 3Y0.17%
5. Dividend
5.1 Amount
AQB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AQUABOUNTY TECHNOLOGIES
NASDAQ:AQB (4/26/2024, 7:00:00 PM)
1.95
+0.1 (+5.41%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap7.53M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.7% | ||
| ROE | -16.7% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.8 | ||
| Quick Ratio | 0.68 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-19.19%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y38.09%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-20.88%
Revenue growth 3Y166.94%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y